XML 40 R25.htm IDEA: XBRL DOCUMENT

SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition

The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three months ended March 31, 2024 (in thousands):


	Three Months Ended March 31,
	2024
Revenue from Janssen Collaboration Agreement:





Over Time:
Research and Development Services	$	971
Clinical Supply Services	2
Total Revenue from Janssen Collaboration Agreement	$	973

The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three months ended March 31, 2024 (in thousands):


	Three Months Ended March 31, 2024
	Mundipharma		Melinta
Revenue from Collaboration, License and Commercial Agreements:
Point in Time:


License of Intellectual Property - upon milestone achieved	$	813	$	—

Product Revenue	2,826		—
Royalty Revenue	26		76
Over Time:
Research and Development Services	3,266		317
Clinical Supply Services	166		—

Total Revenue from Collaboration, License and Commercial Agreements	$	7,097	$	393